During the past decade, University of Michigan, Kellogg Eye Center conducted 59 clinical trials. In the 10-year time frame, 59 clinical trials started and 21 clinical trials were completed, i.e. on average, 35.6% percent of trials that started reached the finish line to date. In the past 5 years, 26 clinical trials started and 17 clinical trials were completed. i.e. 65.4% of trials that started reached the finish line.

Out of the total clinical trials conducted in "University of Michigan, Kellogg Eye Center" #1 sponsor was "University of Michigan" with 13 trials, followed by "Neurotech Pharmaceuticals" with 7 trials sponsored, "Jaeb Center for Health Research" with 6 trials sponsored, "MeiraGTx UK II Ltd" with 5 trials sponsored and "Aura Biosciences" with 5 trials sponsored. Other sponsors include 42 different institutions and companies that sponsored additional 38 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "University of Michigan, Kellogg Eye Center" #1 collaborator was "National Eye Institute (NEI)" with 10 trials as a collaborator, "Foundation Fighting Blindness" with 4 trials as a collaborator, "National Institutes of Health (NIH)" with 3 trials as a collaborator, "Regeneron Pharmaceuticals" with 3 trials as a collaborator and "The Lowy Medical Research Institute Limited" with 2 trials as a collaborator. Other collaborators include 46 different institutions and companies that were collaborators in the rest 55 trials.

According to Clinical.Site data, the most researched conditions in "University of Michigan, Kellogg Eye Center" are "Retinitis Pigmentosa" (11 trials), "Eye Diseases" (5 trials), "Eye Diseases, Hereditary" (5 trials), "Eye Disorders Congenital" (4 trials) and "Macular Telangiectasia Type 2" (4 trials). Many other conditions were trialed in "University of Michigan, Kellogg Eye Center" in a lesser frequency.

Most popular intervention types in "University of Michigan, Kellogg Eye Center" are "Drug" (38 trials), "Device" (13 trials), "Biological" (12 trials), "Other" (11 trials) and "Procedure" (7 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (10 trials), "NT-501" (3 trials), "Ciliary neurotrophic factor (CNTF)" (2 trials), "LX201" (2 trials) and "Lampalizumab" (2 trials). Other intervention names were less common.

The vast majority of trials in "University of Michigan, Kellogg Eye Center" are 74 trials for "All" genders, 6 trials for "Male" genders and 1 trials for "Female" genders.

Currently, there are 27 active trials in "University of Michigan, Kellogg Eye Center". 2 are not yet recruiting, 11 are recruiting, 13 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 39 completed trials in University of Michigan, Kellogg Eye Center, undefined suspended trials, and 11 terminated clinical trials to date.

Out of the total trials that were conducted in University of Michigan, Kellogg Eye Center, 11 "Phase 1" clinical trials were conducted, 29 "Phase 2" clinical trials and 21 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 8 trials that are defined as “Not Applicable".